Frazier Life Sciences Management, L.P.
Q3 2026 13F-HR Holdings
Net value change ($000)
-561,472
(-12.2%)
New positions
7
Sold out positions
4
Turnover %
16.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2026
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ATTOVIA THERAPEUTICS INC | 120,773 | NEW |
| BRAVEHEART BIO INC | 106,400 | NEW |
| Ascendis Pharma AS | 51,297 | NEW |
| MNKD | 33,330 | 118.5% |
| CLDX | 29,172 | NEW |
| MBX | 22,750 | 6.2% |
| PARABILIS MEDICINES INC | 22,688 | 43.2% |
| ACRS | 19,862 | 76.2% |
| SRPT | 19,495 | NEW |
| ZLAB | 13,963 | 38.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|